| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -9,781,113 | -5,675,312 |
| Research and development-acquired patent, expensed | -850,500 | -850,500 |
| Stock-based compensation | 1,187,929 | 219,929 |
| Stock-based professional fees | 222,100 | 55,525 |
| Lease costs | 2,135 | 3,245 |
| Unrealized loss of crypto assets | -25,305 | - |
| Prepaid expenses and other current assets | - | 155,221 |
| Prepaid expenses | 356,643 | - |
| Change in fair value of investment in joint ventures | - | 0 |
| Accounts payable and accrued expenses | 196,254 | -459,527 |
| Net cash used in operating activities | -7,653,533 | -5,160,861 |
| Purchase of crypto assets | 300,000 | - |
| Net cash used in investing activities | -300,000 | - |
| Proceeds from issuance common stock, net of offering costs | 3,511,556 | 1,508,065 |
| Proceeds from exercise of warrants | 5,625,000 | 5,625,000 |
| Taxes paid related to net share settlement of equity award | 376,000 | - |
| Net cash provided by financing activities | 8,760,556 | 7,133,065 |
| Net increase (decrease) in cash and cash equivalents | 807,023 | 1,972,204 |
| Effect of exchange rate changes on cash | 1,965 | - |
| Cash and cash equivalents at beginning of period | 7,038,923 | - |
| Cash and cash equivalents at end of period | 7,847,911 | - |
Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc. (HOTH)